Achillion's CEO Milind Deshpande steps down; NeuroVision raises $11.2M for novel Alzheimer's detection tech
→ Milind Deshpande is stepping down from Achillion $ACHN, the biotech he’s led for the better part of the last two decades, first as CSO and then as CEO. His departure leaves the faded hep C star in the hands of former COO Joseph Truitt, who already has the president title. During his tenure, Deshpande steered a pipeline restructuring that rebranded Achillion from an infectious disease player to a specialist in complement biology, axing staff just a few months ago. Truitt, who joined the company in 2009, emerged as a key figure in that comeback narrative. Having led commercial strategy and business development, he will now prep Achillion for a series of readouts from its complement factor D inhibitor program in rare diseases.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.